T1	Participants 224 347	patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy
T2	Participants 370 417	Patients with measurable and assessable disease
T3	Participants 700 725	474 patients were treated
